Europe Pharmacogenomics Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (PCR, Sequencing, Microarray, Gel Electrophoresis, Mass Spectrometry, and Others), Application (Drug Discovery, Oncology, Neurology and Psychiatry, Pain Management, Cardiovascular Diseases, and Others), and End User (Hospitals and Clinics, Biopharmaceutical Companies, CROs and CDMOs, and Others)

No. of Pages: 171    |    Report Code: TIPRE00028855    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
Europe Pharmacogenomics Market
Free Sample Buy Now

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. Europe Pharmacogenomics Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. Europe Pharmacogenomics Market – Key Market Dynamics

5.1 Growth Drivers
  • 5.1.1
  • 5.1.2 Increasing demand for personalized medicine
  • 5.1.3 Advancements in genomics and bioinformatics
  • 5.1.4 Rising prevalence of chronic diseases
  • 5.1.5 Growing investments in R&D
  • 5.1.6 Increasing government support for pharmacogenomics research
  • 5.1.7 Rising healthcare expenditure
  • 5.1.8 Growing adoption of pharmacogenomics in clinical practice
5.2 Market Opportunities
  • 5.2.1
  • 5.2.2 Developing novel therapeutic approaches
  • 5.2.3 Identifying drug targets
  • 5.2.4 Predicting drug response and adverse effects
  • 5.2.5 Optimizing drug dosing
  • 5.2.6 Enhancing clinical trial efficiency
  • 5.2.7 Reducing healthcare costs
  • 5.2.8 Improving patient outcomes
  • 5.2.9 Expanding into emerging markets
5.3 Future Trends
  • 5.3.1
  • 5.3.2 Integration of AI and machine learning
  • 5.3.3 Advancements in next-generation sequencing
  • 5.3.4 Development of pharmacogenomic biomarkers
  • 5.3.5 Expansion of direct-to-consumer genetic testing
  • 5.3.6 Increased collaboration between academia, industry, and healthcare providers
  • 5.3.7 Global regulatory framework for pharmacogenomics
  • 5.3.8 Ethical considerations and privacy concerns
  • 5.3.9 Personalized medicine becoming the standard of care
5.4 Impact of Drivers and Restraints

6. Europe Pharmacogenomics Market Regional Analysis

6.1 Europe Pharmacogenomics Market Overview
6.2 Europe Pharmacogenomics Market Revenue 2019-2028 (US$ Million)
6.3 Europe Pharmacogenomics Market Forecast Analysis

7. Europe Pharmacogenomics Market Analysis – by Technology

7.1 PCR
  • 7.1.1 Overview
  • 7.1.2 PCR: Europe Pharmacogenomics Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Sequencing
  • 7.2.1 Overview
  • 7.2.2 Sequencing: Europe Pharmacogenomics Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Microarray
  • 7.3.1 Overview
  • 7.3.2 Microarray: Europe Pharmacogenomics Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Gel Electrophoresis
  • 7.4.1 Overview
  • 7.4.2 Gel Electrophoresis: Europe Pharmacogenomics Market – Revenue and Forecast to 2031 (US$ Million)
7.5 Mass Spectrometry
  • 7.5.1 Overview
  • 7.5.2 Mass Spectrometry: Europe Pharmacogenomics Market – Revenue and Forecast to 2031 (US$ Million)

8. Europe Pharmacogenomics Market Analysis – by Application

8.1 Drug Discovery
  • 8.1.1 Overview
  • 8.1.2 Drug Discovery: Europe Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
8.2 Oncology
  • 8.2.1 Overview
  • 8.2.2 Oncology: Europe Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
8.3 Neurology and Psychiatry
  • 8.3.1 Overview
  • 8.3.2 Neurology and Psychiatry: Europe Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Pain Management
  • 8.4.1 Overview
  • 8.4.2 Pain Management: Europe Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Cardiovascular Diseases
  • 8.5.1 Overview
  • 8.5.2 Cardiovascular Diseases: Europe Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)

9. Europe Pharmacogenomics Market Analysis – by End User

9.1 Hospitals and Clinics
  • 9.1.1 Overview
  • 9.1.2 Cardiovascular Diseases: Europe Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
9.2 Biopharmaceutical Companies
  • 9.2.1 Overview
  • 9.2.2 Cardiovascular Diseases: Europe Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
9.3 CROs and CDMOs
  • 9.3.1 Overview
  • 9.3.2 Cardiovascular Diseases: Europe Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)

10. Europe Pharmacogenomics Market – Europe Analysis

10.1 Europe
  • 10.1.1 Europe Pharmacogenomics Market Breakdown, by Key Country, 2022 and 2028 (%)
  • 10.1.1.1 Europe Pharmacogenomics Market – Revenue and Forecast Analysis – by Country
  • 10.1.1.1 UK: Europe Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.1.1 UK: Europe Pharmacogenomics Market Breakdown, by Technology
    • 10.1.1.1.2 UK: Europe Pharmacogenomics Market Breakdown, by Application
    • 10.1.1.1.3 UK: Europe Pharmacogenomics Market Breakdown, by End User
  • 10.1.1.2 Germany: Europe Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.2.1 Germany: Europe Pharmacogenomics Market Breakdown, by Technology
    • 10.1.1.2.2 Germany: Europe Pharmacogenomics Market Breakdown, by Application
    • 10.1.1.2.3 Germany: Europe Pharmacogenomics Market Breakdown, by End User
  • 10.1.1.3 France: Europe Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.3.1 France: Europe Pharmacogenomics Market Breakdown, by Technology
    • 10.1.1.3.2 France: Europe Pharmacogenomics Market Breakdown, by Application
    • 10.1.1.3.3 France: Europe Pharmacogenomics Market Breakdown, by End User
  • 10.1.1.4 Russia: Europe Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.4.1 Russia: Europe Pharmacogenomics Market Breakdown, by Technology
    • 10.1.1.4.2 Russia: Europe Pharmacogenomics Market Breakdown, by Application
    • 10.1.1.4.3 Russia: Europe Pharmacogenomics Market Breakdown, by End User
  • 10.1.1.5 Italy: Europe Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.5.1 Italy: Europe Pharmacogenomics Market Breakdown, by Technology
    • 10.1.1.5.2 Italy: Europe Pharmacogenomics Market Breakdown, by Application
    • 10.1.1.5.3 Italy: Europe Pharmacogenomics Market Breakdown, by End User
  • 10.1.1.6 Rest of Europe: Europe Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.6.1 Rest of Europe: Europe Pharmacogenomics Market Breakdown, by Technology
    • 10.1.1.6.2 Rest of Europe: Europe Pharmacogenomics Market Breakdown, by Application
    • 10.1.1.6.3 Rest of Europe: Europe Pharmacogenomics Market Breakdown, by End User

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. Europe Pharmacogenomics Market Industry Landscape

12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Abbott
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 F. HOFFMANN-LA ROCHE LTD.
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 Oxford Nanopore Technologies
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 THERMO FISHER SCIENTIFIC INC.
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 Illumina, Inc.
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
13.6 QIAGEN
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
13.7 Agilent Technologies, Inc.
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
13.8 Myriad Genetics, Inc.
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - E Market

  1. Abbott
  2. F. HOFFMANN-LA ROCHE LTD.
  3. Oxford Nanopore Technologies
  4. THERMO FISHER SCIENTIFIC INC.
  5. Illumina, Inc.
  6. QIAGEN
  7. Agilent Technologies, Inc.
  8. Myriad Genetics, Inc.
europe-pharmacogenomics-market